- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02000622
Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (OlympiAD)
March 29, 2024 updated by: AstraZeneca
A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.
This open label, randomised, controlled, multi-centre phase III study will assess the efficacy and safety of single agent olaparib vs standard of care based on physician's choice of capecitabine, vinorelbine or eribulin in metastatic breast cancer patients with gBRCA 1/2 mutations.
Study Overview
Status
Active, not recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
302
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Plovdiv, Bulgaria, 4000
- Research Site
-
Plovdiv, Bulgaria, 4004
- Research Site
-
Sofia, Bulgaria, 1233
- Research Site
-
Sofia, Bulgaria, 1330
- Research Site
-
Sofia, Bulgaria, 1303
- Research Site
-
Sofia, Bulgaria, 1504
- Research Site
-
Varna, Bulgaria, 9010
- Research Site
-
Vratza, Bulgaria, 3000
- Research Site
-
-
-
-
-
Beijing, China, 100142
- Research Site
-
Beijing, China, 100021
- Research Site
-
Beijing, China, 100006
- Research Site
-
Changchun, China, 130061
- Research Site
-
Changsha, China, 410013
- Research Site
-
Chengdu, China, 610041
- Research Site
-
Dalian, China, 116011
- Research Site
-
Guangzhou, China, 510060
- Research Site
-
Hangzhou, China, 310022
- Research Site
-
Harbin, China, 150081
- Research Site
-
Nanjing, China, 210009
- Research Site
-
Shanghai, China, 200032
- Research Site
-
Shanghai, China, 200025
- Research Site
-
Shenyang, China, 110016
- Research Site
-
Tianjin, China, 300060
- Research Site
-
-
-
-
-
Brno, Czechia, 656 53
- Research Site
-
Olomouc, Czechia, 775 20
- Research Site
-
Praha 2, Czechia, 128 08
- Research Site
-
-
-
-
-
Caen Cedex, France, 14076
- Research Site
-
Montpellier, France, 34298
- Research Site
-
Rouen, France, 76038
- Research Site
-
Strasbourg Cedex, France, 67065
- Research Site
-
Villejuif, France, 94800
- Research Site
-
-
-
-
-
Budapest, Hungary, 1083
- Research Site
-
Budapest, Hungary, 1115
- Research Site
-
Budapest, Hungary, 1145
- Research Site
-
Budapest, Hungary, 1122
- Research Site
-
Budapest, Hungary, 1032
- Research Site
-
Nyíregyháza, Hungary, 4400
- Research Site
-
Veszprém, Hungary, 8200
- Research Site
-
-
-
-
-
Bologna, Italy, 40138
- Research Site
-
Napoli, Italy, 80131
- Research Site
-
Padova, Italy, 35128
- Research Site
-
Roma, Italy, 00168
- Research Site
-
Roma, Italy, 00144
- Research Site
-
Rozzano, Italy, 20089
- Research Site
-
-
-
-
-
Chuo-ku, Japan, 104-0045
- Research Site
-
Chuo-ku, Japan, 104-8560
- Research Site
-
Fukuoka-shi, Japan, 811-1395
- Research Site
-
Kagoshima-shi, Japan, 892-0833
- Research Site
-
Nagoya-shi, Japan, 464-8681
- Research Site
-
Osaka-city, Japan, 540-0006
- Research Site
-
Sapporo-shi, Japan, 003-0804
- Research Site
-
Shinagawa-ku, Japan, 142-8666
- Research Site
-
Suita-city, Japan, 565-0871
- Research Site
-
-
-
-
-
Cheongju-si, Korea, Republic of, 28644
- Research Site
-
Daegu, Korea, Republic of, 41404
- Research Site
-
Incheon, Korea, Republic of, 21565
- Research Site
-
Seongnam-si, Korea, Republic of, 13620
- Research Site
-
Seoul, Korea, Republic of, 03722
- Research Site
-
Seoul, Korea, Republic of, 03080
- Research Site
-
Seoul, Korea, Republic of, 158-710
- Research Site
-
Seoul, Korea, Republic of, 6351
- Research Site
-
-
-
-
-
Estado de México, Mexico, 50080
- Research Site
-
Merida, Mexico, 97000
- Research Site
-
Merida, Mexico, 97133
- Research Site
-
Mexico, Mexico, 6760
- Research Site
-
Mérida, Mexico, 97070
- Research Site
-
San Juan del Rio, Mexico, 76800
- Research Site
-
-
-
-
-
Cusco, Peru, CUSCO 01
- Research Site
-
Lima, Peru, LIMA 27
- Research Site
-
Lima, Peru, LIMA 34
- Research Site
-
Lima, Peru, LIMA 41
- Research Site
-
Lima, Peru, LIMA 01
- Research Site
-
Lima, Peru, Lima 18
- Research Site
-
San Borja, Peru, LIMA 41
- Research Site
-
-
-
-
-
Elbląg, Poland, 82-300
- Research Site
-
Gdańsk, Poland, 80-214
- Research Site
-
Grzepnica, Poland, 72-003
- Research Site
-
Tarnobrzeg, Poland, 39-400
- Research Site
-
Warszawa, Poland, 03-291
- Research Site
-
Warszawa, Poland, 01-748
- Research Site
-
Łódź, Poland, 93-513
- Research Site
-
-
-
-
-
Bucharest, Romania, 013811
- Research Site
-
Bucuresti, Romania, 011171
- Research Site
-
Bucuresti, Romania, 030171
- Research Site
-
Cluj Napoca, Romania, 400015
- Research Site
-
Cluj-Napoca, Romania, 400015
- Research Site
-
-
-
-
-
Arkhangelsk, Russian Federation, 163045
- Research Site
-
Ivanovo, Russian Federation, 153040
- Research Site
-
Moscow, Russian Federation, 115478
- Research Site
-
Omsk, Russian Federation, 644013
- Research Site
-
Saint Petersburg, Russian Federation, 195271
- Research Site
-
Saint Petersburg, Russian Federation, 197022
- Research Site
-
Saint Petersburg, Russian Federation, 195257
- Research Site
-
Saransk, Russian Federation, 430005
- Research Site
-
St-Petersburg, Russian Federation, 197758
- Research Site
-
St.Petersburg, Russian Federation, 191014
- Research Site
-
Yaroslavl, Russian Federation, 150054
- Research Site
-
-
-
-
-
Barcelona, Spain, 08003
- Research Site
-
Córdoba, Spain, 14004
- Research Site
-
Granada, Spain, 18014
- Research Site
-
Madrid, Spain, 28034
- Research Site
-
Majadahonda, Spain, 28222
- Research Site
-
Oviedo, Spain, 33011
- Research Site
-
Sevilla, Spain, 41013
- Research Site
-
Valencia, Spain, 46026
- Research Site
-
Zaragoza, Spain, 50009
- Research Site
-
-
-
-
-
Bern, Switzerland, CH-3010
- Research Site
-
Lausanne, Switzerland, CH-1011
- Research Site
-
Zürich, Switzerland, 8063
- Research Site
-
-
-
-
-
Kaohsiung, Taiwan, 80756
- Research Site
-
Taichung, Taiwan, 407
- Research Site
-
Taipei, Taiwan, 10449
- Research Site
-
Taipei, Taiwan, 11217
- Research Site
-
Taipei, Taiwan, 10048
- Research Site
-
Taoyuan, Taiwan, 333
- Research Site
-
-
-
-
-
Adana, Turkey, 1260
- Research Site
-
Ankara, Turkey, 06230
- Research Site
-
Edirne, Turkey, 22030
- Research Site
-
Gaziantep, Turkey, 27310
- Research Site
-
Istanbul, Turkey, 34390
- Research Site
-
Izmir, Turkey, 35100
- Research Site
-
Kayseri, Turkey, 38039
- Research Site
-
Konya, Turkey, 42080
- Research Site
-
Mersin, Turkey, 33110
- Research Site
-
-
-
-
-
Aberdeen, United Kingdom, AB25 2ZN
- Research Site
-
Colchester, United Kingdom, CO4 5JL
- Research Site
-
Coventry, United Kingdom, CV2 2DX
- Research Site
-
London, United Kingdom, W6 8RF
- Research Site
-
Manchester, United Kingdom, M20 4BX
- Research Site
-
Plymouth, United Kingdom, PL6 8DH.
- Research Site
-
-
-
-
California
-
San Diego, California, United States, 92123
- Research Site
-
Santa Rosa, California, United States, 95403
- Research Site
-
Whittier, California, United States, 90602
- Research Site
-
-
Colorado
-
Denver, Colorado, United States, 80204
- Research Site
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Research Site
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Research Site
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Research Site
-
Orlando, Florida, United States, 32804
- Research Site
-
Plantation, Florida, United States, 33324
- Research Site
-
-
Georgia
-
Columbus, Georgia, United States, 31904
- Research Site
-
Marietta, Georgia, United States, 30060
- Research Site
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Research Site
-
Niles, Illinois, United States, 60714
- Research Site
-
-
Kansas
-
Wichita, Kansas, United States, 67214
- Research Site
-
-
Louisiana
-
Lafayette, Louisiana, United States, 70506
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Research Site
-
Boston, Massachusetts, United States, 02215
- Research Site
-
Boston, Massachusetts, United States, 02118
- Research Site
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Research Site
-
Grand Rapids, Michigan, United States, 49503
- Research Site
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905-0001
- Research Site
-
Saint Louis Park, Minnesota, United States, 55416
- Research Site
-
-
Mississippi
-
Jackson, Mississippi, United States, 39202
- Research Site
-
-
Missouri
-
Columbia, Missouri, United States, 65212
- Research Site
-
Saint Louis, Missouri, United States, 63131
- Research Site
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
- Research Site
-
-
New York
-
Commack, New York, United States, 11725
- Research Site
-
Harrison, New York, United States, 10604
- Research Site
-
New York, New York, United States, 10021
- Research Site
-
New York, New York, United States, 10065
- Research Site
-
Rockville Centre, New York, United States, 11570
- Research Site
-
Syracuse, New York, United States, 13210
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
- Research Site
-
Cleveland, Ohio, United States, 44195
- Research Site
-
Cleveland, Ohio, United States, 44106
- Research Site
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Research Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Research Site
-
Sayre, Pennsylvania, United States, 18840
- Research Site
-
-
Tennessee
-
Germantown, Tennessee, United States, 38138
- Research Site
-
-
Texas
-
Houston, Texas, United States, 77030
- Research Site
-
Tyler, Texas, United States, 75701
- Research Site
-
-
Vermont
-
Burlington, Vermont, United States, 05401
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 99 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Germline mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious.
- Histologically or cytologically confirmed breast cancer with evidence of metastatic disease.
- Prior therapy with an anthracycline and a taxane in either an adjuvant or metastatic setting.
- Prior platinum allowed as long as no breast cancer progression occurred on treatment or if given in adjuvant/neoadjuvant setting at least 12 months from last dose to study entry elapsed.
- ER/PR breast cancer positive patients must have received and progressed on at least one endocrine therapy (adjuvant or metastatic), or have disease that the treating physician believes to be inappropriate for endocrine therapy.
- ECOG performance status 0-1.
- Adequate bone marrow, kidney and liver function.
Exclusion Criteria:
- Prior treatment with PARP inhibitor.
- Patients with HER2 positive disease.
- More than 2 prior lines of chemotherapy for metastatic breast cancer.
- Untreated and/or uncontrolled brain metastases.
- Prior malignancy unless curatively treated and disease-free for > 5 years prior to study entry. Prior adequately treated non-melanoma skin cancer, in situ cancer of the cervix, DCIS or stage I grade 1 endometrial cancer allowed.
- Known HIV (Human Immunodeficiency Virus) infection.
- Pregnant or breast-feeding women.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Olaparib
Olaparib tablet 300mg bd po
|
Patients will be administered olaparib orally twice daily (bid) at 300 mg.
Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water.
|
Active Comparator: Physician's choice chemotherapy
Capecitabine 2500 mg/m2 d1-14 q 21, or Vinorelbine 30 mg/m2 d1,8 q 21, or Eribulin 1.4 mg/m2 d1,8 q 21
|
Investigators will declare one of the following regimens:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1)
Time Frame: Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.
|
Time from randomisation to the earliest of objective radiological progression or death by any cause in the absence of objective progression.
Objective radiological progression is defined using Response Evaluation Criteria In Solid Tumours (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
|
Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Second Progression or Death (PFS2)
Time Frame: Second progression status reviewed every 8 weeks following the first objective radiological progression as per investigator assessment. Assessed up to a maximum of 30 months.
|
Time from randomisation to the earliest of the progression event subsequent to the first objective radiological progression, or death.
Second progression may involve any of; objective radiological or symptomatic progression or death.
Objective radiological progression is defined using Response Evaluation Criteria In Solid Tumours (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Symptomatic progression is assessed by investigators based on clinical examination.
|
Second progression status reviewed every 8 weeks following the first objective radiological progression as per investigator assessment. Assessed up to a maximum of 30 months.
|
Overall Survival (OS)
Time Frame: Survival status reviewed every 3 weeks until treatment discontinued, then every 8 weeks. Assessed up to a maximum of 30 months.
|
Time from randomisation until death due to any cause.
|
Survival status reviewed every 3 weeks until treatment discontinued, then every 8 weeks. Assessed up to a maximum of 30 months.
|
Objective Response Rate (ORR) Using Blinded Independent Central Review (BICR) Data Assessed by Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1)
Time Frame: Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.
|
Number of responders according to blinded independent central review (BICR) assessment.
Per Response Evaluation Criteria In Solid Tumours Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR) is defined as the disappearance of all target lesions; Partial Response (PR) is defined as >=30% decrease in the sum of the longest diameter of target lesions; Overall Response = CR + PR.
|
Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.
|
Adjusted Mean Change in Global Health Status/Quality of Life (QoL) Score From the European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire (EORTC QLQ-C30)
Time Frame: EORTC QLQ-C30 assessments performed at baseline then every ~6 weeks until objective radiological disease progression. Assessed up to a maximum of 30 months.
|
Change from baseline in global health status/quality of life (QoL) score assessed using a mixed model for repeated measures (MMRM) analysis, including all post-baseline global health status/QoL scores up to the latest scheduled visit where at least 20 patients on each treatment arm have a score.
Global health status/QoL score is on a scale from 0 to 100.
A higher score represents an improved health status/QoL.
|
EORTC QLQ-C30 assessments performed at baseline then every ~6 weeks until objective radiological disease progression. Assessed up to a maximum of 30 months.
|
Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) in Patients Confirmed as Myriad CDx gBRCAm
Time Frame: Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.
|
Time from randomisation to the earliest of objective radiological progression or death by any cause in the absence of objective progression.
Objective radiological progression is defined using Response Evaluation Criteria In Solid Tumours Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Assessed in patients with a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future BRCA mutation assays (gene sequencing and large rearrangement analysis).
|
Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.
|
Overall Survival (OS) at Final OS
Time Frame: Survival status reviewed every 3 weeks until treatment discontinued, then every 8 weeks. Assessed up to a maximum of 40 months.
|
Time from randomisation until death due to any cause.
|
Survival status reviewed every 3 weeks until treatment discontinued, then every 8 weeks. Assessed up to a maximum of 40 months.
|
Overall Survival (OS) at Extended OS
Time Frame: Survival status reviewed every 3 weeks until treatment discontinued, then every 8 weeks until Sep 2017 (final OS DCO), then every 3 months. Assessed up to a maximum of 64 months.
|
Time from randomisation until death due to any cause.
|
Survival status reviewed every 3 weeks until treatment discontinued, then every 8 weeks until Sep 2017 (final OS DCO), then every 3 months. Assessed up to a maximum of 64 months.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to First Subsequent Cancer Therapy or Death (TFST)
Time Frame: Subsequent cancer therapy status reviewed every 8 weeks following study treatment discontinuation. Assessed up to a maximum of 30 months.
|
Time from randomisation to the earliest of first subsequent cancer therapy start date following study treatment discontinuation, or death.
|
Subsequent cancer therapy status reviewed every 8 weeks following study treatment discontinuation. Assessed up to a maximum of 30 months.
|
Time to Second Subsequent Cancer Therapy or Death (TSST)
Time Frame: Subsequent cancer therapy status reviewed every 8 weeks following study treatment discontinuation. Assessed up to a maximum of 30 months.
|
Time from randomisation to the earliest of second subsequent cancer therapy start date following study treatment discontinuation, or death.
|
Subsequent cancer therapy status reviewed every 8 weeks following study treatment discontinuation. Assessed up to a maximum of 30 months.
|
Time to First Subsequent Cancer Therapy or Death (TFST) at Extended OS
Time Frame: Subsequent cancer therapy status reviewed every 8 weeks following study treatment discontinuation until Sep 2017 (final OS DCO), then every 3 months. Assessed up to a maximum of 64 months.
|
Time from randomisation to the earliest of first subsequent cancer therapy start date following study treatment discontinuation, or death.
|
Subsequent cancer therapy status reviewed every 8 weeks following study treatment discontinuation until Sep 2017 (final OS DCO), then every 3 months. Assessed up to a maximum of 64 months.
|
Time to Second Subsequent Cancer Therapy or Death (TSST) at Extended OS
Time Frame: Subsequent cancer therapy status reviewed every 8 weeks following study treatment discontinuation until Sep 2017 (final OS DCO), then every 3 months. Assessed up to a maximum of 64 months.
|
Time from randomisation to the earliest of second subsequent cancer therapy start date following study treatment discontinuation, or death.
|
Subsequent cancer therapy status reviewed every 8 weeks following study treatment discontinuation until Sep 2017 (final OS DCO), then every 3 months. Assessed up to a maximum of 64 months.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Mark Robson, MD, Memorial Sloan-Kettering Cancer Center, New York
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 27, 2014
Primary Completion (Actual)
December 9, 2016
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
November 18, 2013
First Submitted That Met QC Criteria
November 27, 2013
First Posted (Estimated)
December 4, 2013
Study Record Updates
Last Update Posted (Actual)
April 1, 2024
Last Update Submitted That Met QC Criteria
March 29, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D0819C00003
- 2013-005137-20 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD Sharing Time Frame
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles.
For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD Sharing Access Criteria
When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool .
Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access.
For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer Metastatic
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
GlycoMimetics IncorporatedTerminatedBreast Cancer | Breast Cancer Metastatic | HR+ Metastatic Breast CancerUnited States
-
BriaCell Therapeutics CorporationRecruitingBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer Metastatic | End Stage CancerUnited States
-
OBI Pharma, IncCompletedMetastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric CancerTaiwan
-
Massachusetts General HospitalPuma Biotechnology, Inc.; Celcuity, Inc.WithdrawnMetastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer | Stage IV (Metastatic) Breast CancerUnited States
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | Postmenopausal Women | Locally Advanced Metastatic Breast CancerIsrael
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedMetastatic Breast Cancer | Metastatic Triple Negative Breast CancerJapan, Belgium, France, Netherlands
-
BriaCell Therapeutics CorporationLumaBridgeEnrolling by invitationBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer MetastaticUnited States
-
Prof. Wolfgang JanniEli Lilly and CompanyRecruitingHormone Receptor-positive Metastatic Breast Cancer | HER2-negative Metastatic Breast CancerGermany, Switzerland
-
Hoffmann-La RocheCompletedHER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast CancerUnited States
Clinical Trials on Olaparib
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingSmall Cell Lung Carcinoma | Small-cell Lung CancerUnited States
-
AstraZenecaMerck Sharp & Dohme LLC; Iqvia Pty LtdCompletedMalignant Solid TumorBelgium
-
CSPC Ouyi Pharmaceutical Co., Ltd.CompletedHealthy ParticipantsChina
-
Dana-Farber Cancer InstituteNovartis; AstraZenecaCompleted
-
AstraZenecaEuropean Network of Gynaecological Oncological Trial Groups (ENGOT)CompletedEpithelial Ovarian CancerDenmark, France, Germany, Italy, Spain, Poland, Belgium, Canada, United Kingdom, Israel, Norway
-
Nordic Society of Gynaecological Oncology - Clinical...Hellenic Cooperative Oncology Group; European Network of Gynaecological Oncological... and other collaboratorsRecruiting
-
AstraZenecaMerck Sharp & Dohme LLC; European Network of Gynaecological Oncological Trial... and other collaboratorsActive, not recruitingRelapsed Ovarian Cancer | Following Complete or Partial Response to Platinum Based Chemotherapy | Platinum Sensitive | BRCA MutatedKorea, Republic of, France, China, Italy, United States, Israel, United Kingdom, Canada, Japan, Germany, Brazil, Netherlands, Belgium, Poland, Australia, Russian Federation, Spain
-
SandozCompleted
-
Qilu Pharmaceutical Co., Ltd.Completed
-
Leiden University Medical CenterUniversity Medical Center Groningen; Erasmus Medical CenterRecruitingBRCA1 Mutation | BRCA2 Mutation | Homologous Recombination Deficiency | Ovarian Neoplasm EpithelialNetherlands